Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis

Current Opinion in Pulmonary Medicine

Volumn 21, Issue 5, 2015, Pages 479-489

  King, Christopher S ^a   Nathan, Steven D ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Idiopathic pulmonary fibrosis; Interstitial lung disease; Nintedanib; Pirfenidone

Indexed keywords

NINTEDANIB; PIRFENIDONE; INDOLE DERIVATIVE; PYRIDONE DERIVATIVE;

DIARRHEA; DRUG EFFICACY; DRUG TREATMENT FAILURE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG FUNCTION; MALAISE; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RASH; REVIEW; TREATMENT DURATION; CLINICAL TRIAL (TOPIC); IDIOPATHIC PULMONARY FIBROSIS; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PYRIDONES; TREATMENT OUTCOME;

EID: 84942905255     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000190     Document Type: Review

References (34)

1. Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis: FDA review of pirfenidone and nintedanib. N Engl J Med 2015; 372:1189-1191.
2. Idiopathic Pulmonary Fibrosis Clinical Research N. Martinez FJ, de Andrade JA, Anstrom KJ, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2093-2101.
3. Idiopathic Pulmonary Fibrosis Clinical Research N. Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366:1968-1977.
4. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186:88-95.
5. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374:222-228.
6. Selman M, King TE, Pardo A, et al. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-151.
7. Ahluwalia N, Shea BS, Tager AM. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med 2014; 190:867-878.
8. Gunther A, Korfei M, Mahavadi P, et al. Unravelling the progressive patho-physiology of idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21:152-160.
9. Spagnolo P, Wells AU, Collard HR. Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug Discov Today 2015; 20:514-524.
10. Kim ES, Keating GM. Pirfenidone: a review of its use in idiopathic pulmonary fibrosis. Drugs 2015; 75:219-230.
11. Takeda Y, Tsujino K, Kijima T, et al. Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Prefer Adherence 2014; 8:361-370.
12. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45:1434-1445.
13. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171:1040-1047.
14. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35:821-829.
15. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377:1760-1769.
16. Jones MG, Fletcher S, Richeldi L. Idiopathic pulmonary fibrosis: recent trials and current drug therapy. Respiration 2013; 86:353-363.
17. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083-2092.
18. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365:1079-1087.
19. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071-2082.
20. Potts J, Yogaratnam D. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis. Ann Pharmacother 2013; 47:361-367.
21. Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther 2014; 31:375-391.
22. Woodcock HV, Molyneaux PL, Maher TM. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Des Devel Ther 2013; 7:503-510.
23. US FDA. Ofev capsules: US prescribing information. http://www.accessda ta.fda.gov.
24. Roth GJ, Binder R, Colbatzky F, et al. Nintedanib: from discovery to the clinic. J Med Chem 2015; 58:1053-1063.
25. Loveman E, Copley VR, Scott DA, et al. Comparing new treatments for idiopathic pulmonary fibrosis - A network meta-analysis. BMC Pulm Med 2015; 15:37.
26. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011; 140:221-229.
27. Okuda R, Hagiwara E, Baba T, et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 2013; 107:1431-1437.
28. Costabel U, Albera C, Bradford WZ, et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31:198-205.
29. Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev 2015; 24:58-64.
30. Arai T, Inoue Y, Sasaki Y, et al. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig 2014; 52:136-143.
31. Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 2014; 88:199-207.
32. Chaudhuri N, Duck A, Frank R, et al. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med 2014; 108:224-226.
33. Nathan S, Albera C, Bradford W, et al. Effect of continued treatment with pirfenidone following a clinically meaningful decline in percentage predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med 2015; 191:A1016.
34. Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2015; 45:1382-1392.